Tag: HER2

Get up to speed with the latest trends and developments in digital pathology – Join Visiopharm at this year’s Pathology Visions, Oct 1-3, San Diego, California

| August 22, 2017 | 0 Comments

During the event, we will be showcasing our entire digital pathology portfolio. Here we are particularly proud to share our work in advancing PD-L1 testing based on the patented VirtualTripleStaining™ and its utility in automated assessment of Ki-67 in breast cancers.  In addition, you will be able to see examples from our new HER2 quality […]

Continue Reading

OptraSCAN Digital Pathology Launches On-Demand Image Analysis Suite at USCAP 2017

| March 6, 2017 | 0 Comments

Affordable and scanner agnostic image analysis solutions utilizing artificial intelligence for colorimetric and morphometric analysis for oncology, neuroscience and toxicological pathology SUNNYVALE, CA–(BUSINESS WIRE)—OptraSCAN, Inc. today announced the launch of its next generation, On-Demand suite of image analysis software for digital pathology, which includes OptraASSAYSTM, CARDSTM and OptraPROCESSTM. The image analysis suite supports both individual, […]

Continue Reading

Come Challenge the Computer with Visiopharm at USCAP 2017

| March 3, 2017 | 0 Comments

Join Visiopharm at USCAP 2017 and learn about how we are transforming pathology! Come see demonstrations of Analysis of PD-L1 and CD Markers within the Tumor Micro-Environment Visualize and quantify biomarker expression with heatmaps and automated hot-spot detection The new, ultra-fast viewer which can be integrated into your digital pathology workflow Visit our booth to […]

Continue Reading

Slidematch™ now features Alignment of Brightfield and Fluorescence Whole Slide Images

| February 20, 2017 | 0 Comments

Munich, 20 February 2017 — microDimensions launches a new version of its high precision whole slide alignment software Slidematch. With the new version users can align digital whole slide images from consecutive sections in brightfield and fluorescence mode, e.g. for the evaluation of the HER2 status of cancer patients.  While brightfield images (e.g. stained in […]

Continue Reading

Register Now for CAP Webinar on HER2 Testing in Gastroesophageal Adenocarcinoma

| January 13, 2017 | 0 Comments

  In 2010, results of a phase 3 randomized controlled trial showed that targeted therapy directed against HER2 statistically significantly prolonged overall survival compared with chemotherapy alone in patients with HER2–positive advanced GEA. Because there are important differences in HER2 expression, scoring, and outcomes in GEA relative to breast carcinoma, the need for guideline recommendations […]

Continue Reading

ASCO, CAP, and ASCP Issue Joint Guideline on HER2 Testing in Gastroesophageal Cancers

| November 16, 2016 | 0 Comments

The American Society of Clinical Oncology (ASCO), the College of American Pathologists (CAP) and the American Society for Clinical Pathology (ASCP) have issued a joint guideline on HER2 testing for patients with gastroesophageal cancers. Read the full guideline and

Continue Reading

Proscia Introduces New Image Analysis Applications – Expands its Pathology Cloud Platform

| October 26, 2016 | 0 Comments

New applications on the platform enable acceleration of breakthroughs in the fight against cancer. Baltimore, MD; San Diego, CA (PRWEB) October 24, 2016 — Proscia Inc, the industry’s leading provider of cloud solutions for digital pathology, announced today the availability of powerful image analysis applications for cancer research on the company’s Proscia Pathology Cloud platform […]

Continue Reading

OptraSCAN Announces the Availability of a Breast Cancer-Focused Panel of Algorithmic Biomarkers as Part of its On-Demand Model

| July 14, 2016 | 0 Comments

OptraSCANTM On-Demand Digital Pathology announced today the availability of a Breast Cancer Focused Panel of Algorithmic Biomarkers (ER/PR, HER-2/neu, Ki67, P53, EGFR, AE1/AE3) through its OptraASSAYSTM and OptraCARDSTM Solutions, as part of its subscription-based model (starting at $1,950 per month for a six-month commitment, which includes: the OptraSCAN Scanner, Data Storage, TELEPath Telepathology and Service). […]

Continue Reading

Philips Teams Up With Visiopharm to Boost Breast Cancer Diagnosis Objectivity Through Computational Pathology

| June 22, 2016 | 0 Comments

More news from Philips this week – announcing a licensing agreement with Visiopharm to combine Visiopharm’s breast cancer panel with Philips’ Intellisite digital pathology solution. From a scientific standpoint, as the references mentioned point out, image analysis is critical to appropriate patient care, increasing consistency and reproducibility, if not accuracy, with increased efficiencies for pathologists […]

Continue Reading

Use of Aperio Image Analysis in Peer Reviewed Breast Cancer Research

| April 14, 2016 | 0 Comments

Leica Biosystems was kind enough to share with me a recent white paper on “Use of Aperio Image Analysis in Peer Reviewed Breast Cancer Research” This is a lengthy review of 30 articles published in peer-reviewed scientific journals, which use Aperio Image Analysis for research into aspects of breast cancer, including disease development, prognostic markers, and clinical […]

Continue Reading

Join Omnyx for a Webinar!

| April 10, 2016 | 0 Comments

Quantification Algorithms: Value and Progress in Standardization of IHC Breast Tissue Data April 13th, 2016 12:00 PM EST Michael Grunkin, Ph.D. Chief Executive Officer Visiopharm In collaboration with Visiopharm®, Dynamyx™ software provides pathologists sophisticated tools that incorporate precision, quantification and confidence in decision-making for breast panel analysis (HER2, ER, PR, Ki67). These algorithms give pathologists […]

Continue Reading

“Herceptoid” and “Personalized” Medicine

| September 30, 2015 | 0 Comments

Over the summer a longtime friend asked if I could review some slides for a friend of his, or actually from his friend’s wife. Of course I agreed to do so. He mentioned that she had “metastatic breast cancer” and wanted to make sure the slides fit that diagnosis to insure she was getting the […]

Continue Reading

Applied Spectral Imaging received South Korean Ministry of Food and Drug Safety (MFDS) Clearance for GenASIs™ HiPath IHC Family for HER2, ER, PR and Ki67

| April 16, 2015 | 0 Comments

Carlsbad, CA. – April 16, 2015 – Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that it has received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) for its GenASIs HiPath image capture and analysis platform. The South Korean market is a key market for ASI’s computer-aided imaging solutions for pathology, which […]

Continue Reading

Accuracy of HER2 Testing in Gastric Cancer

| April 5, 2015 | 0 Comments

With almost 1 million new cases per year, gastric cancer is currently the number four most common malignant disease. Today, there is no universal standard treatment. Recently, however, the ToGA trial demonstrated efficacy of Trastuzumab (Herceptin) for gastric and gastro-oesophageal (G/GEJ) patients who are over-expressing HER2. In 2010, the FDA approved Trastuzumab for treatment of […]

Continue Reading